| Oct 16 |
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
|
| Oct 16 |
Novocure shares soar 33% as FDA approves lung cancer treatment
|
| Oct 16 |
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
|
| Oct 15 |
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
|
| Oct 15 |
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
|
| Oct 15 |
Novocure gets FDA approval for its lung cancer treatment
|
| Oct 9 |
NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
|
| Oct 1 |
Novocure to Report Third Quarter 2024 Financial Results
|
| Sep 9 |
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
|
| Sep 6 |
Why NovoCure Stock Dived by 13% This Week
|
